Consideration of anticancer therapeutic agents in early gastric cancer
10.19538/j.cjps.issn1005-2208.2019.05.15
- Author:
Yi-lin LIU
1
;
Xiao-tian ZHANG
1
Author Information
1. Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute Beijing 100142,China
- Publication Type:Journal Article
- Keywords:
early gastric cancer;
recurrence;
anticancer therapeutic agents
- From:
Chinese Journal of Practical Surgery
2019;39(05):467-469
- CountryChina
- Language:Chinese
-
Abstract:
Early gastric cancer is mainly treated withradical resection by either endoscopic resection or radical surgery. but there arestill patients finally developrecurrence and metastasis. There are arguments on how to identify these patients with poor prognosis,and how to manage the treatment,and the value and timing ofanticancer therapeutic agents. Because of low level of evidence, the current clinical guidelines are relatively vague on these questions, and oncologists differ in treatment optionin real world. The role of anticancer therapeutic agents in early gastric cancer needs to be re-examined given the advances in molecular biology,bioinformatics and new drugs.
